NanoThea’s goal is to create innovative methods for cancer diagnostics and radiotherapy, offering precise targeting and minimizing side effects. Through advanced nanoparticle technology and polysaccharide conjugates with targeting systems, we are able to enhance the effectiveness of radiotherapy and ensure a higher level of safety for patients. Unique features of our products include: - The structure of nanoparticles or conjugates with a targeting system, enabling precise delivery of therapeutic substances to the tumor, reducing negative effects on the patient’s health. - Appropriately designed linkers and selected chelators for specific radioisotopes to ensure radiochemical stability. - Non-toxicity – the materials used in our products are non-toxic and FDA-approved for safety. - In-situ radio-labeling at the hospital, allowing for the labeling of radioisotopes directly before administration to the patient. NanoThea is a company developing innovative radiopharmaceuticals to support the diagnosis and treatment of cancer. Our unique approach to radioisotope carriers focuses on ensuring optimal availability of nanoparticles and conjugates for cancer cells distributed throughout the body. Compared to traditional solutions, our products offer greater precision, safety, and effectiveness. NanoThea’s technology allows for the attachment of various metal chelators to nanoparticles and conjugates, enabling their use in PET and SPECT diagnostics with radioactive isotopes such as Ga, Cu, or In, combined with Gd for magnetic resonance imaging (MRI), as well as for radiotherapy using Lu or Y. Additionally, through the use of precise targeting agents, our solutions can be directed towards different types of cancer, providing a personalized approach to treatment.
